PainTEQ has been awarded two new patents for its pioneering LinQ® procedure, further solidifying its position as a leader in sacroiliac (SI) joint dysfunction treatment. These patents mark a notable step forward in medical device innovation, offering new hope to thousands suffering from debilitating lower back pain.

"With these two new patents plus the three patents granted in 2023, PainTEQ now boasts a total of 14 patents. This portfolio underscores PainTEQ's commitment to advancing treatments for sacroiliac joint pain," said Sean LaNeve, CEO of PainTEQ.

US patent number 11,963,883 (April 23, 2024) relates to the design of the LinQ allograft implant for the sacroiliac joint. The implant design features include dimensional characteristics to enhance the bone-implant interface, a large unobstructed graft window to promote faster and more robust bone formation, and ridges to mechanically lock the implant securely in place for long-term stability. Overall, the LinQ implant design provides features conducive to both stability and bone growth, which are advantageous for optimizing patient outcomes.

US patent number 11,931,053 (March 19, 2024) relates to the design of the company's proprietary single-use joint decorticator tool, used to prepare opposing bony surfaces for joint fusion. The tool design simplifies the process of decortication with innovative tool alignment features to help guide a physician in proper positioning and a lever-action removal system to allow precise extraction control with minimal effort. These design features, along with the decorticator's single-use basis, support enhanced procedure efficiency while prioritizing patient safety.

"I have used other systems in the past and couldn't buy into their style. This system from PainTEQ has been a home run every time. I'm really impressed," said Dr. Marc Lynch, Medical Director, Synovation Medical Group, CA.